Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit

Abstract

Aim: The aim is to compare microbiological examination of samples, which were taken by fiberoptic BAL and protected mini-BAL methods from patients with diagnosis of pneumonia in the intensive care unit.

Methods: Study population included all adult critically ill mechanically ventilated patients, who were admitted to Intensive Care Units of Cerrahpasa Medical School between July 2013 and November 2014, and diagnosed as pneumonia either on admission or during their stay. Patients were assessed by APACHE II, SOFA and CPIS. The patients were randomly allocated in to two groups using computer generated random numbers. In the first group FOB and BAL was applied first followed by protected mini-BAL, in the second group protected mini-BAL was the first sampling method. The samples were then transferred to the microbiology laboratory for microbiologic examination. The materials were evaluated by gram-staining and quantitative cultures. The compability of fiberoptic BAL and protected mini-BAL results for all cases was evaluated with kappa statistics. A two tailed p value of <0.05 was considered statistically significant.

Results: Sixty-six patients were included in to the study. Fiberoptic BAL followed by protected mini-BAL was performed in 32 (48.5%) patients, protected mini-BAL followed by fiberoptic BAL in 34 (51.5%) patients. No significant difference was found between two groups about demographic features, severity scores, laboratory values, use of antibiotics, comorbidities and prognosis. When the types of pathogens were compared between two groups no significant differences were found. When the results of samples were evaluated for compatibility all together, the Kappa coefficient was found as 0.476 (p=0.0001), which is not high value, and this kappa coefficient is considered to be moderate value.

Conclusion: Protected mini-BAL procedure is effective, less invasive and easier to apply compared to FOB. But it cannot be used as an alternative to fiberoptic BAL to determine the causative organism of pneumonia in ICU patients according to this study results.

Keywords: Pneumonia; BAL; FOB; Protected mini-BAL; Intensive care unit; VAP

Introduction

Pneumonia is a common respiratory problem, which involves infection of the alveoli, inflammation and consolidation of the lung tissue. Pneumonia is common in intensive care (ICU) patients, and carries a risk of high mortality in the affected patients. Pneumonia is identified by using a combination of imaging, clinical and laboratory criteria. Timely diagnosis and treatment with antibiotics is life saving however, there is no gold standart for the diagnosis of pneumonia. One of the criteria of pneumonia established by Centers for Disease Control and Prevention (CDC) is getting semi-quantitative or non-quantitative cultures of sputum obtained by deep cough, induction, aspiration or lavage.

Procedure, which used to obtain samples from airways is important because of the contamination risk from upper airways, which makes defining the causative organism difficult, and leads to use inappropriate antibiotics. To prevent this contamination from upper airways, the use flexible fiberoptic bronchoscopy (FOB) is suggested. But use of FOB is complex and needs expertise. Protected mini-broncoalveolar lavage (protected mini-BAL) can also be used instead of FOB. This procedure is not as difficult and complicated as FOB and does not take much time as in FOB, but there is still doubt about the accuracy of culture results in protected mini-BAL.

The aim of this study is to evaluate compatibility of the quantitative cultures in microbiological specimens taken with FOB and protected mini-BAL from ICU patients who are diagnosed as pneumonia.

Material and Method

The study was approved by the Clinical Research Ethics
Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit

Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit

Positive

Negative

2

Diffused

<4.000 or >11.000

No infiltrate

≥39 or ≤36

1

0

>240 or ARDS

<4.000 or >11.000 + band forms ≥ 500

≤240 and no evidence of ARDS

Gurlevik A, Urukmez S, Utku T, Dikmen Y (2017) Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit. J Anesth Crit Care Open Access 7(2): 00256. DOI:

Citation: Gurlevik et al.

Table 1: Algorithm for Clinically-Defined Pneumonia (CDC 2013 guideline).

| Radiology | Signs/Symptoms/Laboratory |
|-----------|---------------------------|
| Two or more serial chest radiographs with at least one of the following: New or progressive and persistent infiltrate, Consolidation, Cavitation. | At least one of the following: |
| | 1. New onset or worsening cough, or dyspnea or tachypnea |
| | 2. Leukopenia (<4000 WBC/mm3) or leukocytosis (≥12,000 WBC/mm3) |
| | 3. For adults ≥70 years old, altered mental status with no other recognized cause and At least two of the following: |
| | A. New onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements |
| | B. New onset or worsening cough, or dyspnea or tachypnea |
| | C. Rales or bronchial breath sounds |
| | D. Worsening gas exchange (e.g., O₂ desaturations (e.g., PaO₂/FiO₂ ≤ 240), increased oxygen requirements, or increased ventilator demand) |
| WBC: White Blood Cell; PaO₂/FiO₂: The Ratio of the Arterial Tension (PaO₂) to the Inspiratory Fraction of Oxygen (FiO₂). |

Table 2: Clinical Pulmonary Infection Score (CPIS).

| CPIS Points | 0 | 1 | 2 |
|-------------|---|---|---|
| Tracheal secretions | Rare | Abundant | Abundant+purulent |
| Chest X-ray infiltrates | No infiltrate | Diffused | Localized |
| Temperature, °C | ≥36.5 and ≤38.4 | ≥38.5 and ≤38.9 | ≥39 or ≥36 |
| Leukocytes count, per mm³ | ≥4.000 and ≤11.000 | <4.000 or >11.000 | <4.000 or >11.000 + band forms ≥ 500 |
| PaO₂/FiO₂, mmHg | >240 or ARDS | ≤240 and no evidence of ARDS |
| Microbiology | Negative | Positive |

ARDS: Acute respiratory distress syndrome; PaO₂/FiO₂: The Ratio of the Arterial Tension (PaO₂) to the Inspiratory Fraction of Oxygen (FiO₂).
Statistics

Statistical analysis of the data was performed using SPSS 22.0 package program (SPSS, IBM Ltd, Chicago, USA). Results are expressed in frequency, percentage or mean and standard deviation when appropriate. Parametric data was compared using Mann-Whitney U test, Pearson’s chi-square and Fisher Exact tests were used for non-parametric data. The compatibility of fiberoptic BAL and protected mini-BAL results for all cases was evaluated with kappa statistics. A two tailed p value of <0.05 was considered statistically significant.

Results

Sixty-six patients were included in to the study, demographic features are given in Table 3. Fiberoptic BAL followed by protected mini-BAL was performed in 32 (48.5%) patients, protected mini-BAL followed by fiberoptic BAL in 34 (51.5%) patients. No significant differences were found in the demographic features of two groups.

Of the patients 22 (33.3%) of 66 had Community Acquired Pneumonia (CAP), 25 (37.9%) had Ventilator Associated Pneumonia (VAP) and 19 (28.8%) had Hospital Acquired Pneumonia (HAP). Fifty-eight (87%) patients had comorbidities, which increase the mortality risk such as diabetes, hypertension, congestive heart failure and chronic obstructive lung disease.

In 83.3 % of patients (55/66) antimicrobial therapy was started prior to pneumonia diagnosis for prophylaxis or treatment of an infection in other parts of the body. Mortality in this patients population was 77.27%. No significant difference was found between two groups about severity scores, laboratory values, use of antibiotics, comorbidities and prognosis (Table 3). When the types of pathogens were compared between two groups no significant differences were found. The types are listed in Table 4. When the types of bacteria obtained from two techniques regardless of group allocation (timing of procedure) were compared no statistically significant difference was observed (Table 5). The compatibility of cultures obtained by fiberoptic BAL and protected mini-BAL in patients, who were diagnosed as pneumonia were 81.81% in CAP (18/22), 73.68% in HAP (14/19) and 64% in VAP(16/25). When the results of samples were evaluated for compatibility all together, the Kappa coefficient was found as 0.476 (p=0.001).

### Table 3: Demographic features and patients’ condition

| Patient’s features       | First group (FOB-BAL) | Second group (Protected mini-BAL) | p     |
|--------------------------|-----------------------|-----------------------------------|-------|
|                          | n (%)                 | n (%)                             |       |
| Gender (F/M)             | 9/23 (28.1)/71.9      | 18/16 (52.9)/47.1                 | 0.04  |
| Use of antibiotics       |                       |                                   |       |
| No                       | 3 (9.4)               | 8 (23.5)                          | 0.123 |
| Yes                      | 29 (90.6)             | 26 (76.5)                         |       |
| Comorbidities            |                       |                                   |       |
| No                       | 3 (9.4)               | 5 (14.7)                          | 0.39  |
| Yes                      | 29 (90.6)             | 29 (85.3)                         |       |
| Prognosis                |                       |                                   |       |
| Exitus                   | 24 (75.0)             | 27 (79.4)                         | 0.669 |
| Age                      | 68.7 (14.9)           | 61.2 (17.6)                       | 0.061 |
| ICU length of stay       | 34.4 (27.9)           | 38.4 (42.6)                       | 0.944 |
| APACHE II                | 23.6 (5.7)            | 21.8 (6.2)                        | 0.313 |
| SOFA                     | 8.6 (3.1)             | 8.6 (3.2)                         | 0.637 |
| CPIS                     | 6.5 (1.2)             | 6.6 (1.1)                         | 0.403 |
| White Blood Cells count, per mm³ | 12.404 (6.578) | 15.460 (14.927) | 0.404 |
| CRP                      | 167.0 (129.6)         | 190.3 (119.6)                     | 0.281 |

*Sd: Standart Deviation; APACHE: Acute Physiologic, Assessment and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CPIS: Clinical Pulmonary Infection Score; CRP: C Reaktive Protein*
Table 4: The types of pathogens were compared between two groups.

| Procedure          | Pathogens                        | First group | Second group | P value |
|--------------------|----------------------------------|-------------|--------------|---------|
|                    |                                  | n          | %            | n       | %       |         |
|                    | Acinetobacter baumannii          | 3          | 9.40%        | 2       | 5.90%   | 0.552   |
|                    | Pseudomonas aeruginosa           | 1          | 3.10%        | 1       | 2.90%   | 0.5     |
|                    | Corinobacterium species          | 1          | 3.10%        | 0       | 0.00%   | 0.449   |
|                    | Staphylococcus aureus (MSSA and MRSA) | 0         | 0.00%        | 1       | 2.90%   | -       |
|                    | Stenotrophomonas species         | 2          | 6.20%        | 0       | 0.00%   | 0.551   |
|                    | Streptococcus pneumoniae        | 0          | 0.00%        | 1       | 2.90%   | -       |
| Fiberoptic BAL     | Klebsiella species               | 1          | 3.10%        | 0       | 0.00%   | -       |
|                    | Gram pozitif difteroid rods     | 1          | 3.10%        | 0       | 0.00%   | 0.5     |
|                    | Candida species                 | 3          | 9.40%        | 6       | 17.60%  | 0.552   |
|                    | No pathogen                     | 4          | 12.50%       | 2       | 5.90%   | 0.159   |
|                    | Multiple pathogens              | 16         | 50.00%       | 21      | 61.80%  | 0.748   |
| Protected Mini-BAL | Acinetobacter baumannii         | 2          | 6.20%        | 1       | 2.90%   | 0.549   |
|                    | Pseudomonas aeruginosa          | 0          | 0.00%        | 2       | 5.90%   | 0.451   |
|                    | Corinobacterium türleri         | 1          | 3.10%        | 0       | 0.00%   | -       |
|                    | Staphylococcus aureus (MSSA and MRSA) | 2         | 6.20%        | 1       | 2.90%   | 0.5     |
|                    | Stenotrophomonas species         | 1          | 3.10%        | 1       | 2.90%   | 0.5     |
|                    | Streptococcus pneumoniae        | 0          | 0.00%        | 1       | 2.90%   | -       |
|                    | Gram pozitif difteroid rods     | 1          | 3.10%        | 0       | 0.00%   | -       |
|                    | Candida species                 | 2          | 6.20%        | 5       | 14.70%  | 0.553   |
|                    | No pathogen                     | 11         | 34.40%       | 5       | 14.70%  | 0.35    |
|                    | Multiple pathogens              | 12         | 37.50%       | 18      | 52.90%  | 0.711   |

Table 5: Total number of pathogens regardless the priority of the procedure.

| Pathogens                        | Fiberoptic BAL | Protected Mini-BAL | p     |
|----------------------------------|----------------|--------------------|-------|
|                                  | n          | %            | n       | %       |       |
| Acinetobacter baumannii          | 5          | 7.6           | 3       | 4.5     | 0.571 |
| Pseudomonas aeruginosa           | 2          | 3             | 2       | 3       | 0.5   |
| Corinobacterium species          | 1          | 1.5           | 1       | 1.5     | 0.5   |
| Staphylococcus aureus (MSSA ve MRSA) | 1         | 1.5           | 3       | 4.5     | 0.43  |
| Stenotrophomonas species         | 2          | 3             | 2       | 3       | 0.5   |
| Streptococcus pneumoniae        | 1          | 1.5           | 1       | 1.5     | 0.5   |
| Klebsiella species               | 1          | 1.5           | 0       | 0       | -     |
| Gram pozitif difteroid rods     | 1          | 1.5           | 1       | 1.5     | 0.5   |
| Candida species                 | 9          | 13.6          | 7       | 10.6    | 0.574 |
| No pathogens                     | 6          | 9.1           | 16      | 24.2    | 0.17  |
| Multiple pathogens              | 37         | 56.1          | 30      | 45.5    | 0.807 |

Citation: Gurlevik A, Urkmez S, Ubu T, Dikmen Y (2017) Comparison of Bronchoalveolar Lavage and Protected Mini- Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit. J Anesth Crit Care Open Access 7(2): 00256. DOI: 10.15406/jaccoa.2017.07.00256
Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit

Discussion

Pneumonia, either community acquired or health care associated is a serious problem. Main threatment option is antibiotics. It has been shown that when treatment with appropriate antibiotics is initiated promptly the mortality is low. Choosing the appropriate antibiotic is problematic due to difficulties in finding the causative organisms. Because of this difficulty broad spectrum antibiotics are generally used, at least initially until microbiological evaluations are performed.

In intensive care patients samples obtained by endotracheal suctioning may give erroneous results due to contamination from colonized upper airways. That's why clinicians need to obtain dependable lower respiratory tract samples, which are not contaminated. Microbiological evaluation of the specimens obtained with bronchoscopy is considered as the specific diagnostic approach to determine the causative microorganism in pneumonia. However bronchoscopy is invasive, requires expertise, expensive, needs longer time to perform, disturb oxygenation, respiratory mechanics and hemodynamics during the procedure in intensive care patients. Therefore an easier to perform technique is needed. Protected mini-BAL is easier to perform, needs less expertise, takes less time and have lesser effects on oxygenation or hemodynamics, and is cheaper. Sensitivity and specificity of protected mini-BAL was found to be 66-100 and 66-96 in different studies. These results are compatible with fiberoptic bronoscopic BAL. Broncoscopy is not indicated as a routine diagnostic test for some certain group of pneumonias like CAP, and should restricted to selected individuals with severe forms or unresponded to initial therapy and require additional investigations of pneumonia. It has been published that patients with progressive pneumonia acceptable as non-responding to traditional diagnostic procedures could be improved clinically by using bronoscopic investigations. In present study, severe CAP cases were included (22 cases; 33.3% of all cases) primarily according to their clinicall severity, and applied FOB as a diagnostic tool.

The mortality rates varies according to patients score of illness, already taken antibiotics, advanced age, comorbidities and failing to initial therapies including non-invasive mechanical ventilation and need to further MV therapy. On the basis of this approach it has been reported a wide variety of mortality rate between 28-85%. The mortality rate presented in this study is thought higher then expected (77.27%). Our explanation for such a higher rate while actual APACHE II score was 23.6 and predicted mortality rate was 48.2%; in enrolled patients, it had been already prescribed and failed multi antibiotics, have high co-morbidity rates, all suffered severe respiratory failure with hypoxemia during admission to ICU. Furthermore, length of stay in ICU was long (38.4 days) and organ dysfunctions during that time of long period realized (SOFA: 8.6) and, cultured multiple pathogens. We argue that all these particular factors during the period stay in ICU contributed to high mortality rate.

Rouby et al. used protected mini-BAL in hospital acquired pneumonia patients. Protected mini-BAL was %74 compatible with the pathologic evaluation of postmortem lung tissue in terms of microbiological accuracy. They suggested that protected mini-BAL could be used instead of bronchoscopy. In a different study endotracheal aspirates (ETA) and protected mini-BAL were compared in 82 VAP patients and protected mini-BAL was found to be more sensitive. Khilnani et al. evaluated bronchoscopic and nonbronchoscopic techniques for diagnosis of VAP and calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for this techniques, taking CPIS of ≥ 6 as reference standart. Sensitivity, specificity, PPV and NPV for nonbronchoscopic BAL were found similar to bronchoscopic BAL and there were good microbiologic concordance among this procedure. Ost et al. compared the effectiveness of ETA fiberoptic BAL and protected mini-BAL in the diagnosis and management of ventilator associated pneumonia. They found no difference in mortality but protected mini-BAL had lowered costs and antibiotic use.

Early ventilator associated pneumonia diagnosis requires to reduce VAP mortality and to delay emergence of multidrug-resistant microorganisms. The commonest organisms isolated in VAP are Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumanii in intensive care unit. However, causative organisms vary between intensive care. Artuk et al. studied protected mini-BAL vs endotracheal aspirates (ETA) in VAP patients: Acinetobacter baumanii, Pseudomonas aeruginosa and Staphylococcus aureus rates were %53, %20, %20 in protected mini-BAL, %10, %20, %20 in ETA. In our study BAL and miniBAL were compared and in both procedures mostly multiple types of pathogens were found and when evaluated one by one, mostly gram negative microorganisms were the reason of VAP. Tasbakan et al. compared fiberoptic BAL and protected mini-BAL in immunocompromised patients in the ICU and found no significant difference in two methods. They have found 12 patients with Candida albicans with both procedures. In this study Candida species were found in 9 BAL and 7 protected mini-BAL samples.

When we compared the microbiological results between two groups with kappa score, Kappa ratio 0.476 (p=0.0001), which is not high value, and this kappa coefficient is considered to be moderate value. However, we were not able to compare keppa scores between CAP, VAP and HAP subgroups because of the inadequate number of cases.

The priority of the procedure was changed in two groups (half of the patients BAL was applied first and protected mini-BAL was first in the other half). The aim of this change was to see if the priority makes a difference in microbiologio results. Especially we wanted to see if 100 cc of 0.9% saline effect the results of protected mini-BAL because of dilution. Four of the 32 patients who were applied BAL in the first line had no pathogens in BAL cultures and 11 of 32 had no pathogens in protected mini-BAL. This seems to make a big difference but statistically there was no significant difference between two groups.

Conclusion

Protected mini-BAL procedure is effective, less invasive and easier to apply compared to FOB. But it cannot be used as an alternative to fiberoptic BAL to determine the causative organism of pneumonia in ICU patients.

Citation: Gurlevik A, Urmey S, Uba T, Dikmen Y (2017) Comparison of Bronchoalveolar Lavage and Protected Mini-Bronchoalveolar Lavage in Diagnosis of Pneumonia in Intensive Care Unit. J Anesth Crit Care Open Access 7(2): 00256. DOI: 10.15406/jacca.2017.07.00256
Acknowledgement

This study was supported by Istanbul University Scientific Research Projects Unit (SRP) (Project number 29608).

References

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44.

2. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated and health care associated pneumonia. Am J Respir Crit Care Med 171: 388-416.

3. Fagon J, Patrick H, Haas DW (2000) Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin dalfopristin versus vancomycin. Am J Respir Crit Care Med 161: 753-762.

4. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, et al. (2008) Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36: 1089-1096.

5. The Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355: 2619-2630.

6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections. Am J Infect Control 16: 128-140.

7. (2013) CDC/HNS Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting. AJIC 34:5: 310-332.

8. Luna CM, Blanazco D, Niederman MS, Matarucco W, Baredes NC, et al. (2003) Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31: 676-682.

9. Alvarez-Lern A (1996) Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired pneumonia study group. Intensive Care Med 22: 387-394.

10. Ioanas M, Ferrer R, Angrill J, Ferrer M, Torres A (2001) Microbiological investigation in ventilator-associated pneumonia. Eur Respir J 17: 791-801.

11. Fagon JY (2006) Diagnosis and treatment of ventilator-associated pneumonia fiberoptic bronchoscopy with bronchoalveolar lavage is essential. Semin Respir Crit Care Med 27: 34-44.

12. Shorr AF, Shernher JL, Jackson WL, Kollef MH (2005) Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 33: 46-53.

13. Schnabel RM, Van der Velden K, Osniski A, Rohde G, Roeckaerts PMH, et al. (2015) Clinical course and complications following diagnostic bronchoalveolar lavage in critically ill mechanically ventilated patients. BMC Pulmonary Medicine 15: 107.

14. Cracco C, Fortoukh M, Prodanovic H, Asohay E, Chenivesse C, et al. (2013) Safety of performing fiberoptic bronchoscopy in critically ill hypoxic patients with acute respiratory failure. Intensive Care Med 39: 45-52.

15. Estella A (2010) Effects on respiratory mechanics of bronchoalveolar lavage in mechanically ventilated patients. J bronchole & interv pulmonol17: 228-231.

16. Du Rand IA, Blakley J, Botoon R, Chaudhuri N, Gupta V, et al. (2013) British Thoracic Society Bronchoscopy Guideline Group. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 68: 11-44.

17. Fujitani S, Yu VL (2006) Diagnosis of ventilator-associated pneumonia: Focus on nonbronchoscopic techniques [nonbronchoscopic bronchoalveolar lavage, including mini-BAL, blind protected specimen brush, and blind bronchial sampling] and endotracheal aspirates. Intensive Care Med 21: 17-21.

18. Campbell GD (2000) Blinded invasive diagnostic procedures in ventilator associated pneumonia. Chest 117: 207-211.

19. Kollef MH, Bock KR, Richards RD, Hearns ML (1995) The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Int Med 122: 743-748.

20. El-Shabrawy M, El-Sokkary RH (2016) Role of fiberoptic broncoscopy and BAL in assessment of the patient with non-responding pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis 65: 613-620.

21. Chalmers JD, Mandal P, Singnanayagam A (2011) Severity assessment tools to guide ICU admission in community – acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 37: 1409-1420.

22. Montosa G, Amaya MDD, Diaz HM, Balsara EC (2015) Analysis of the mortality rate in patients admitted to the ICU for severe community acquired pneumonia. Crit Care 19(Suppl): S1.

23. Ertugral BM, Yildirim A, Ay P (2006) Ventilator-associated pneumonia in surgical emergency intensive care unit. Saudi Med J 27(1): 52-57.

24. Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC (2010) Ventilator-associated pneumonia: a review. Eur J Intern Med 21(5): 360-368.

25. Rouby JJ, Rossignon MD, Nicolas MH, Martin de Lassale E, Cristin S, et al. (1989) Viars P. A prospective study of protected bronchial lavage in the diagnosis of nosocomial pneumonia. Anesthesiology 71: 679-685.

26. Anora SC, Mudallar YM, Lee C, Mitchell D, Iredell J, et al. (2002) Non-bronchoscopic bronchoalveolar lavage in the microbiological diagnosis of pneumonia in mechanically ventilated patients. Anaesth Intensive Care 30: 11-20.

27. Khilhani GC, Arafath TL, Hadda V, Kapil A, Sood S, et al. (2011) Comparison of bronchoscopic and nonbronchoscopic techniques for diagnosis of ventilator associated pneumonia. Indian J Crit Care Med 15: 16-23.

28. Ost DE, Hall CS, Joseph G (2003) Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 168: 1060-1067.

29. Shaw MC (2005) Ventilator-associated pneumonia. Curr Opin Pulm Med 11: 236-241.

30. Arut C, Guc HC, Mert G, Karagak A, Bedir O, et al. (2012) Comparison of endotracheal aspirate culture and protected mini-BAL culture in the diagnosis of ventilator-associated pneumonia. Microbiol Biul 46: 421-431.

31. Taşbakan MS, Gürgün A, Başoğlu OK, Ekerken PK, Pulukucu H, et al. (2011) Comparison of Bronchoalveolar Lavage and Mini-Bronchoalveolar Lavage in the Diagnosis of Pneumonia in Immunocompromised Patients. Respiration 81: 229-235.